SANTA MONICA, Calif., Jan. 9, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced the appointment of Claudine Prowse, Ph.D., to the newly created position of Senior Vice President, Corporate Communications and Investor Relations (IR). Dr. Prowse will be primarily responsible for driving the Company's communication strategy and initiatives. She will report to Ms. Cynthia M. Butitta, Chief Financial Officer and Chief Operating Officer.
"On behalf of management and the Board of Kite, I am pleased to welcome Claudine to our leadership team," said Ms. Butitta. "Claudine is an accomplished communications executive with a keen sense of the critical role science and innovation play in creating value, who has deep experience in working with a broad base of stakeholders including stockholders, patients and providers."
Dr. Prowse has 15 years of experience in the healthcare sector in IR, Corporate Communications, and Institutional Equities Research. Most recently, Dr. Prowse served as the Vice President of Investor Relations at Biogen Idec (Nasdaq:BIIB). She holds a B.S. in Biomedical Engineering from the University of California, San Diego (UCSD) School of Engineering and a Ph.D. in Biomedical Sciences from the UCSD School of Medicine.
About Kite Pharma
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on eACT™ designed to restore the immune system's ability to recognize and eradicate tumors. In partnership with the NCI Surgery Branch through a Cooperative Research and Development Agreement (CRADA), Kite is advancing a pipeline of proprietary eACT™ peripheral blood product candidates, both CAR (chimeric antigen receptor) and TCR (T cell receptor) products, directed to a wide range of cancer indications. Kite is based in Santa Monica, CA. For more information on Kite Pharma, please visit www.kitepharma.com.
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability and willingness of the NCI to continue research and development activities relating to eACT™ pursuant to the CRADA. Various factors may cause differences between Kite's expectations and actual results as discussed in greater detail in Kite's filings with the Securities and Exchange Commission, including without limitation in its Form 10-Q for the quarter ended September 30, 2014. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
CONTACT: Kite Contacts: Claudine Prowse SVP, Corporate Communications and Investor Relations email@example.com Cynthia M. Butitta Chief Financial Officer and Chief Operating Officer 310-824-9999 For Media: Justin Jackson Burns McClellan (212) 213-0006 firstname.lastname@example.org
Source:Kite Pharma, Inc.